Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) EBITDA (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed EBITDA for 10 consecutive years, with -$47.1 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 14.08% to -$47.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$192.0 million through Dec 2025, up 27.68% year-over-year, with the annual reading at -$202.7 million for FY2025, 23.45% up from the prior year.
  • EBITDA for Q4 2025 was -$47.1 million at Rhythm Pharmaceuticals, up from -$52.7 million in the prior quarter.
  • The five-year high for EBITDA was -$34.4 million in Q1 2021, with the low at -$139.9 million in Q1 2024.
  • Average EBITDA over 5 years is -$49.6 million, with a median of -$44.7 million recorded in 2021.
  • The sharpest move saw EBITDA tumbled 166.29% in 2024, then soared 66.4% in 2025.
  • Over 5 years, EBITDA stood at -$51.0 million in 2021, then increased by 17.43% to -$42.1 million in 2022, then rose by 1.99% to -$41.3 million in 2023, then grew by 0.02% to -$41.3 million in 2024, then decreased by 14.08% to -$47.1 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$47.1 million, -$52.7 million, and -$45.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.